Who Supplies Mycophenolate to India from ISRAEL

To import finished pharmaceutical formulations containing Mycophenolate into India, the foreign manufacturer must obtain an Import Registration Certificate and an Import License from the Central Drugs Standard Control Organization (CDSCO). The application process involves submitting detailed product information, including composition, manufacturing process, and stability data. The timeline for obtaining these approvals can vary but typically ranges from 6 to 12 months. For formulations under HS Code 30049099, compliance with the Drugs and Cosmetics Act, 1940, and associated rules is mandatory.

Imported pharmaceutical formulations must undergo quality testing at CDSCO-approved laboratories in India. Each batch requires a Certificate of Analysis (CoA) demonstrating compliance with Indian Pharmacopoeia standards. Stability data, particularly for ICH Zone IV conditions, must be provided to ensure product efficacy and safety. Upon arrival, customs drug inspectors perform port inspections to verify compliance with regulatory standards.

Between 2024 and 2026, the CDSCO has implemented stricter regulations for imported medicines to prevent the sale of unapproved or illegal products in the Indian market. Import registration and licensing have become mandatory, with enhanced scrutiny of manufacturing sites and product dossiers. The introduction of the Production Linked Incentive (PLI) scheme has also impacted the import of finished formulations, encouraging domestic manufacturing and reducing dependency on imports.

India imports finished Mycophenolate formulations primarily due to the availability of patented or branded products not manufactured domestically, specific dosage forms required for patient treatment, and the limited capacity of domestic manufacturers to meet the entire demand. The market size for Mycophenolate formulations in India is substantial, with a growing number of patients requiring immunosuppressive therapy.

The total landed duty for importing Mycophenolate formulations under HS Code 30049099 into India is 17.10%. This includes a Basic Customs Duty (BCD) of 10%, Social Welfare Surcharge (SWS) of 10%, and Integrated Goods and Services Tax (IGST) of 12%. There are no additional duties such as Anti-Dumping Duty or National Calamity Contingent Duty (NCCD) applicable to this product.

India sources Mycophenolate formulations from Israel due to the competitive advantages offered by Israeli manufacturers, including the availability of patented formulations, specialized dosage forms, and high-quality production standards. While other countries like China, Germany, and the United States also supply these formulations, Israel's share in the Indian market is notable due to its established reputation and compliance with international regulatory standards.

India imports Mycophenolate formulations from Israel due to the availability of patented formulations, specialized dosage forms, and high-quality manufacturing standards. Israeli manufacturers offer products that may not be available domestically, fulfilling specific patient needs and treatment protocols.

Compared to other origins like China, the European Union, and the United States, Israel offers competitive pricing, superior quality, and adherence to international regulatory standards. Israeli manufacturers' reliability and consistent product quality provide a unique advantage in the Indian market.

Indian importers face risks such as single-source dependency, currency fluctuations, regulatory changes, quality control issues, and potential shipping disruptions. While there have been no significant shortages reported, it is advisable for importers to diversify their supplier base to mitigate these risks.

1. 1Dual-Sourcing: Engage multiple suppliers to reduce dependency on a single source.
2. 2Inventory Planning: Maintain adequate stock levels to buffer against supply chain disruptions.
3. 3Payment Terms: Negotiate favorable terms such as Letters of Credit (LC) or Documents Against Payment (DA/DP).
4. 4Minimum Order Quantities (MOQs): Align order sizes with market demand to optimize inventory costs.
5. 5Supplier Qualification: Conduct thorough due diligence to ensure supplier reliability and compliance with regulatory standards.

1. 1Obtain an Importer Exporter Code (IEC) from the Directorate General of Foreign Trade (DGFT).
2. 2Apply for a CDSCO Import Registration Certificate for the product.
3. 3Secure a CDSCO Import License (Form 10) for the finished formulation.
4. 4Ensure compliance with the Drugs and Cosmetics Act, 1940, and associated rules.
5. 5Engage a Customs House Agent (CHA) for customs clearance procedures.
6. 6Seek an advance ruling from customs for HS Code 30049099, if necessary.

1. 1Certificate of Analysis (CoA) for each batch.
2. 2Certificate of Pharmaceutical Product (CoPP).
3. 3Good Manufacturing Practice (GMP) certificate.
4. 4Drug Master File (DMF) for the formulation.
5. 5Stability data under ICH Zone IVa/IVb conditions.
6. 6Free Sale Certificate indicating the product is freely sold in the country of origin.
7. 7Manufacturer's authorization letter.

Upon arrival in India, customs drug inspectors perform a thorough inspection of the imported pharmaceutical formulations. Mandatory batch testing is conducted to verify compliance with Indian Pharmacopoeia standards. Samples are collected for laboratory analysis,